founders

David Edwards is the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University, where his work focuses on the fields of fluid mechanics, interfacial transport phenomena, drug delivery, and aerosol science. His current research is supported by grants from the National Institutes of Health and the Bill and Melinda Gates Foundation, and includes the investigation of the fluid mechanical properties of the lung lining fluid that permit control of expired bioaerosol and mitigation of the spread of inhaled infectious disease, the development of novel antibiotic therapies for tuberculosis, and a new delivery platform for needleless childhood vaccines. Dr. Edwards has published over 70 papers on the aerosol delivery of macromolecules to the lung and a variety of related subjects. He is a Fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering. Dr. Edwards is a recipient of numerous awards including the Professional Progress Award of the American Institute of Chemical Engineers, and is a three time awardee of the Ebert Prize of the American Pharmaceutical Association. He is a member of the Advisory Board at the Center for Civilian Biodefense Strategies at the Johns Hopkins University. He is also the scientific founder of Advanced Inhalation Research (AIR), which was acquired by Alkermes, Inc., and Chairman of the Board of the international not-for-profit Medicine in Need (MEND).

Mark J. Gabrielson has been a member of the Ore Board of Directors since 2007, and recently has served as Chairman of the Audit Committee of the Board. Prior to assuming the role of CEO at Ore, he was Managing General Partner of p-Value Capital LLC, a financial services firm focused on investments in biopharmaceutical products. Mark was co-founder and CEO of Pulmatrix Inc. a private venture capital-backed company he launched in 2003 with scientists from Harvard University and MIT that is developing products for respiratory infectious diseases. He is currently on the Board of Directors at Pulmatrix. From 1990 until 2003 Mark was a venture capitalist. He was a General Partner of Prince Ventures, a life sciences focused venture capital firm. The firm’s portfolio included Genentech, Applied Biosystems, Centocor, Regeneron, Inhale Therapeutic Systems and other noteworthy companies. Mark began his career in 1978 at SmithKline Corporation (now GSK) in product management, business development and general management. He was educated at Princeton University.

Dr. Klibanov is currently Professor of Chemistry and Bioengineering at the Massachusetts Institute ofTechnology. His research interests include enzyme chemistry and biotechnology, protein drug delivery and formulation, stability and stabilization of pharmaceutical proteins, and biochemistry in extreme environments. Professor Klibanov has authored over 230 scientific papers and 15 issued U.S. patents and is a member of seven journal editorial boards. He has received numerous prestigious awards including the Leo Friend Award, the Ipatieff Prize, the Marvin J. Johnson Award, and the Arthur C. Cope Scholar Award from the American Chemical Society, as well as the International Enzyme Engineering Prize. He was elected to the National Academy of Sciences and to the National Academy of Engineering of the United States. In addition, Dr. Klibanov has started several biotechnology companies and has been a scientific advisor/consultant for numerous pharmaceutical and chemical companies.

Dr. Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. The only active member of all three U.S. National Academies (the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering), Dr. Langer is one of 14 Institute Professors at MIT. His career has focused on pioneering work at the interface of biotechnology, drug delivery, and materials science, resulting in over 1000 articles and over 600 issued or pending patents worldwide. His patents have further been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology, and medical device companies.

Dr. Langer is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and Advanced Inhalation Research (AIR). Dr. Langer has additionally served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.

Dr. Langer has received over 160 major awards including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. Dr. Langer received his BS from Cornell University, and his ScD from the MIT, both in Chemical Engineering.